Cooperative Agreement UG1HD113241
- Summary Under a $234,292 Project Grant awarded September 13, 2025, by the Fogarty International Center (CFDA 93.989: International Research and Research Training), Impact Research and Development Organisation will develop and pilot test a multilevel, community-based intervention to reduce Pre-Exposure Prophylaxis (PrEP) stigma and increase PrEP uptake among adolescent girls and young women (AGYW) ages 15–24 in western Kenya. The project addresses a critical public health gap, as AGYW represent...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $381,487 to the University of Maryland, Baltimore (UMB) to assess the early implementation of long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) among adolescent girls and young women (AGYW) at high risk of HIV acquisition in Zambia. The key objectives are to: 1) Evaluate implementation determinants of CAB-LA...
- This Project Grant award of $665,225 from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) aims to improve access and adherence to Pre-Exposure Prophylaxis (PrEP) among adolescent girls and young women in Uganda. The 5-year project, titled "SUUBI4PREP: Improving PrEP Access and Adherence Among Adolescent Girls and Young Women in Uganda", will combine peer support interventions with economic empowerment initiatives to address...
- Summary The National Institute of Mental Health (NIMH) awarded a $1,057,586 Project Grant to the Research Foundation of The City University of New York on September 19, 2025, under the Mental Health Research Grants program (CFDA 93.242) to develop and evaluate the Streamlined Treatment and Evidence-Based Adolescent Counseling and Medication Support (STREAMS) intervention. This five-year project, concluding May 31, 2030, will evaluate a combination mental health intervention tailored to...
- PHARMA-GIRL Project Grant Summary The University of California, San Francisco received a $408,643 Project Grant from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) for the period February 1, 2026 through January 31, 2028. The PHARMA-GIRL project conducts implementation science research to evaluate pharmacy-based HIV prevention and treatment service delivery models targeting adolescent...
- This Project Grant award in the amount of $431,712, funded by the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to improve HIV testing among children under five in rural Uganda. The primary goal is to engage with traditional healers to facilitate HIV counseling and testing via oral swab antigen tests for this vulnerable pediatric population. The award supports two key activities: 1) determining barriers and...
- This $5.37 million project grant from the National Institutes of Health National Institute on Drug Abuse will fund the development of a context-aware digital adherence intervention called SMARTSTEPS to improve pre-exposure prophylaxis (PrEP) adherence among men who have sex with men with substance use disorder. The grant will support two phases. Phase I will inform the specification of an algorithm that utilizes digital phenotyping data from a smartphone app to anticipate non-adherence based...
- STEP-UP Project Grant Summary The University of Pennsylvania received a $1,488,558 Project Grant from the National Institute of Mental Health under the Mental Health Research Grants program (CFDA 93.242), awarded September 18, 2025, with completion targeted for September 17, 2028. The grant funds STREAMLINING TELEHEALTH FOR EXPANDED PREP UTILIZATION THROUGH COMMUNITY PARTNERSHIPS (STEP-UP), a three-year observational hybrid implementation-effectiveness pilot study designed to develop and...
- PROTECT AL: PrEP Optimization Through Enhanced Continuum Tracking The National Institute of Mental Health awarded the University of Alabama at Birmingham a $790,198 Project Grant on September 18, 2025, under the Mental Health Research Grants program (CFDA 93.242) to develop and implement PROTECT AL, a data-driven initiative designed to optimize HIV pre-exposure prophylaxis (PrEP) utilization across Alabama's high-incidence areas. The project, extending through May 31, 2030, delivers a...
- This $375,000 federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) aims to evaluate the impact of a status-neutral, person-centric intervention called the "Blue Shed" on HIV transmission and outcomes among people who inject drugs (PWID) in New Delhi, India. The project has three key objectives: Assess the direct impact of the Blue Shed intervention on HIV incidence, viral suppression, and mortality among PWID...
IMPLEMENTATION SCIENCE TO UNDERSTAND AND DESIGN STAKEHOLDER INFORMED INNOVATIVE INTERVENTIONS TO IMPROVE ADOLESCENT AND YOUTH HIV PREVENTION AND CARE CONTINUUMS IN RURAL AND URBAN UGANDA - PROJECT SUMMARY: ADOLESCENTS AND YOUNG ADULTS (AYA) HAVE A HIGH HIV INCIDENCE AND POOR OUTCOMES ALONG THE ENTIRE HIV PREVENTION AND CARE CASCADES COMPARED TO ADULTS. DESPITE THE HIGH HIV BURDEN, BOTH UPTAKE OF ORAL PREP (HIV NEGATIVES) AND ACHIEVING VIRAL SUPPRESSION (HIV POSITIVES) ARE SUB-OPTIMAL AMONG YOUTH IN SUB-SAHARAN AFRICA. AMONG YOUTH IN UGANDA, UPTAKE AND PERSISTENCE ON ORAL PREP IS LOW, WITH REASONS FOR DISCONTINUATION INCLUDING: PILL BURDEN, LOW PERCEIVED SEVERITY OF HIV, NEED FOR PARTNER OR PARENTAL APPROVAL, HIV- RELATED STIGMA, FEAR OF SIDE-EFFECTS AND HEALTH FACILITY BARRIERS. CABOTEGRAVIR, A IS NEW LONG-ACTING ANTIRETROVIRAL (CAB-LA) AND HIGHLY EFFICACIOUS PREP CHOICE THAT CAN MITIGATE BARRIERS TO USE OF DAILY ORAL PREP. WE PROPOSE TO EVALUATE EVIDENCE-BASED HIV PREVENTION AND CARE INTERVENTIONS TO IMPROVE IMPLEMENTATION OUTCOMES AMONG HIGH-RISK AYA (15-24 YEARS) IN UGANDA. THE STUDY COVERS THE CONTINUUM OF CARE, WILL USE NOVEL SCREENING METHODS FOR HIV RISK, WILL INVOLVE TEAMS THAT ARE HIGHLY EXPERIENCED IN YOUTH-FOCUSED CLINICAL TRIALS AND IMPLEMENTATION SCIENCE (IMS), WILL IMPLEMENT MOH APPROVED COMMUNITY DIFFERENTIATED SERVICE DELIVERY MODELS FOR DELIVERY CAB-LA, WILL EVALUATE THE IMPLEMENTATION OF THE SEARCH-YOUTH (SY), A MULTI-COMPONENT INTERVENTION COMPRISING OF LIFE-STAGE BASED ASSESSMENT AND SUPPORT TO INCREASE VIRAL SUPPRESSION IN HIGH-RISK AYA WITH HIV, AND WILL USE HYBRID EFFECTIVENESS IMPLEMENTATION DESIGNS TO ASSESS THESE EVIDENCE-BASED INTERVENTIONS. OUR AIMS INCLUDE: AIM 1: USING THE CONSOLIDATED FRAMEWORK FOR IMPLEMENTATION RESEARCH (CFIR), WE WILL IDENTIFY DETERMINANTS OF POTENTIAL IMPLEMENTATION SUCCESS OF TWO INNOVATIONS: CAB-LA AND SY IMPLEMENTATION AT THE COMMUNITY, CLINIC, PROVIDER, AND PATIENT LEVELS IN 5 GEOGRAPHICALLY DISTINCT SITES IN UGANDA. AIM 2A: USING A HYBRID EFFECTIVENESS IMPLEMENTATION TYPE II DESIGN, WE WILL ASSESS THE UPTAKE AND PERSISTENCE OF CAB-LA. WE WILL CONDUCT A RANDOMIZED PROSPECTIVE STUDY TO ASSESS EFFECTIVENESS FOR THE PROVISION OF CAB- LA AMONG HIGH RISK AYA. EFFECTIVENESS OUTCOME WILL BE PROPORTION OF STUDY SUBJECTS WHO HAVE INITIATED CAB-LA AND PERSISTED AT 18 MONTHS OF FOLLOW-UP COMPARING FACILITY AND COMMUNITY DELIVERY OPTIONS. IMPLEMENTATION OUTCOMES WILL BE FEASIBILITY, ACCEPTABILITY, ADOPTION AND MAINTENANCE USING RE-AIM. AIM 2B: USING A HYBRID EFFECTIVENESS IMPLEMENTATION TYPE III DESIGN WE WILL ASSESS IMPLEMENTATION (FEASIBILITY, ADOPTION, FIDELITY, AND SUSTAINMENT) AND EFFECTIVENESS OF THE SY INTERVENTION IN INCREASING LONG-TERM VIROLOGIC SUPPRESSION (
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $224.8k | 9/19/25 | ||
| Not listed | $200.5k | 9/19/25 | ||
| Not listed | $172.6k | 9/19/25 | ||
| Not listed | ($225k) | 9/17/25 | ||
| Not listed | ($200k) | 9/17/25 |